Takeda and AC Immune Ink Exclusive Deal for Active Immunotherapy in Alzheimer’s, Focusing on Amyloid Beta
Takeda and AC Immune SA have unveiled an exclusive global option and licensing pact concerning AC Immune’s active immunotherapies directed at harmful variants of amyloid beta (Abeta), notably ACI-24.060, intended for Alzheimer’s disease treatment.
ACI-24.060 is a candidate for active immunotherapy against Abeta, aimed at stimulating a strong antibody response to counter the harmful forms of Abeta, which are implicated in the formation of plaques and the advancement of Alzheimer's disease. By promoting the clearance of plaques and effectively preventing their...